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esponsibility of InstAbstract The pregnane X receptor (PXR) plays an important and diverse role in mediating xenobiotic
induction of drug-metabolizing enzymes and transporters. Several protein isoforms of PXR exist, and they
have differential transcriptional activity upon target genes; transcript variants 3 (PXR3) and 4 (PXR4) do
not induce target gene expression, whereas transcript variants 1 (PXR1) and 2 (PXR2) respond to agonist
by activating target gene expression. PXR protein variants also display differences in protein–protein
interactions; PXR1 interacts with p53, whereas PXR3 does not. Furthermore, the transcript variants of
PXR that encode these protein isoforms are differentially regulated by methylation and deletions in the
respective promoters of the variants, and their expression differs in various human cancers and also in
cancerous tissue compared to adjacent normal tissues. PXR1 and PXR4 mRNA are downregulated by
methylation in cancerous tissue and have divergent effects on cellular proliferation when ectopically
overexpressed. Additional detailed and comparative mechanistic studies are required to predict the effect
of PXR transcript variant expression on carcinogenesis, therapeutic response, and the development of
toxicity.
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The pregnane X receptor (PXR), also known as NR1I2 (nuclear
receptor subfamily 1, group I, member 2), SXR (steroid and
xenobiotic sensing receptor), or PAR (pregnane activated receptor),
regulates the expression of proteins involved in all three phases of
drug metabolism and transport. PXR is a nuclear hormone receptor
(NHR), one of a class of proteins characterized by a DNA-binding
domain and activating function domains 1 and 2 (AF-1 and AF-2)
that are relatively conserved in different species and, in PXR
speciﬁcally, by a promiscuous ligand-binding domain (LBD)1–4.
NHRs bind to speciﬁc DNA sequences and bring the DNA molecule
into the preferential steric conditions for transcription of target genes;
in the case of PXR, these are predominantly genes involved in
metabolizing xenobiotics. The LBD of PXR interacts with ligands to
stabilize the protein (and recruit binding proteins, such as RXR,
retinoic X receptor) and enable the recruitment of coactivators to the
AF-2 region, resulting in further stabilization of the protein while in
complex with DNA1–6. PXR regulates the expression of phase I
enzymes, including cytochrome P450 enzymes (CYPs) CYP3A4,
CYP2B6, CYP2C9, and CYP2C19; phase II enzymes, including
UDP-glucuronosyltransferase 1 family polypeptide A1 (UGT1A1),
UGT1A2, and sulfotransferase 2 A (SULT2A); and phase III
transporters, including ATP-binding cassette transporter ABCB1
(also known as MDR1 or P-gp), multiple organic anion transporters
(OATs), and multidrug-resistance protein 3 (MRP3)2–4,7,8. PXR is
mainly expressed in the liver and the intestines9. The recent
identiﬁcation of PXR as a potential therapeutic target in several
diseases underscores the necessity of fully describing all variants of
the receptor and their effect on physiologic and pathophysiologic
processes10–14. PXR has been implicated in the pathophysiology of
bone disease11, inﬂammatory disorders13,14, and dyslipidemias10, in
addition to its roles in hepatotoxicity and hepatic ﬁbrosis15–18.
Because some PXR ligands are species-speciﬁc, a mouse model in
which mouse PXR is replaced with human PXR (hPXR) enables
examination of hPXR function in vivo19–22; however, mouse models
that are engineered to express only PXR variant 1 mRNA (PXR1)
and protein fail to account for the multiple PXR transcripts.
Therefore, a mouse model in which the entire hPXR gene is inserted
into the mouse genome was created21,23.
Ligand activation of PXR results in the induction of target
genes by a broad range of structurally dissimilar xenobiotics,
leading to the metabolism of an even greater range of compounds
than those that directly activate xenobiotic metabolism via
activation of PXR (Table 124–31). Analgesics [NSAIDs (nonster-
oidalanti- inﬂammatory drugs) and non-NSAIDs], protease
inhibitors, antibacterials, anticonvulsants, glucocorticoids, and
statins activate PXR (Table 1). PXR is also activated by a
structurally and functionally diverse set of ligands implicated in
a range of disease states. PXR target genes display considerable
interindividual variation in expression proﬁle and enzymatic
activity32–34. Administration of xenobiotics to patients might cause
adverse drug responses such as hepatotoxicity15,17,35,36. Interindi-
vidual variability in drug response or nonresponse may result, in
part, from variation in total PXR protein expression, single-
nucleotide polymorphisms in coding or promoter regions of
PXR, and variation in the relative expression of PXR isoforms9,32.
Interindividual variability in drug metabolism, therapeutic
response, and the incidence and degree of dose-limiting toxicity
may reﬂect, in part, variability in the expression levels of PXR
transcript variants. There is considerable variability in PXR
transcript expression in human liver and intestines; some patientsexpress low levels of a common variant, whereas others express
high levels of uncommon variants7,9,37–39. These variants display
altered transactivation activity towards target genes7,39. In addi-
tion, PXR1 and PXR2 have separate transcription start sites40.2. PXR and chemotherapeutic metabolism
Distinct from its less investigated direct role in cellular prolifera-
tion and senescence, PXR can play seemingly dual roles in the
development of resistance to chemotherapeutic agents. For exam-
ple, after treatment with a PXR agonist, an inactive anticancer
prodrug is metabolized to a greater degree to an active metabolite
which may confer the anticancer chemotherapeutic activity41.
Conversely, PXR activation may enhance the metabolism of the
active forms of a drug into less active metabolites or excreted, with
a resultant increase in resistance to chemotherapy28,42–60. The role
of PXR in chemotherapeutic metabolism has been elegantly
reviewed by Zhuo61.
Cyclophosphamide and ifosfamide are prodrugs that are con-
verted by CYP3A4 and CYP2B6 to active 4-hydroxy metabo-
lites41. Indeed, the treatment with rifampicin and dexamethasone,
both agonists of PXR, increases the metabolism of the prodrugs to
their 4-hydroxy form to confer anticancer activity41. Irinotecan is a
prodrug that is metabolized by carboxylesterase to its active form
SN38 and is further metabolized by UGT1A1 and, to a lesser
extent, CYP3A4 to an inactive form, SN38 glucuronide
(SN38G)57,58. PXR protein overexpression, and activation by
rifampicin and SN38 itself, results in increased metabolism to
inactive SN38G42,43. Tamoxifen is metabolized to 4-hydroxyta-
moxifen, a more active metabolite, by CYP2D662. Conversely,
tamoxifen is metabolized by CYP3A4 to N-desmethyltamoxifen, a
metabolite with very low activity63. PXR protein overexpression
and activation by rifampicin, SR12813, tamoxifen, and 4-
hydroxytamoxifen lead to increased metabolism to N-desmethyl-
tamoxifen and efﬂux which may result in increased resistance to
chemotherapy48,49,60. Paclitaxel is metabolized by CYP2C8 and
CYP3A4 to inactive metabolites64,65. PXR knockdown by small
interfering RNA (siRNA) or short hairpin RNA (shRNA) results in
increased sensitivity to therapy51,59, whereas the activation of PXR
by rifampicin, paclitaxel, or SR12813 leads to increased metabo-
lism and efﬂux of paclitaxel, resulting in increased resistance to
chemotherapy44,50,51,59. Doxorubicin is metabolized directly by the
Cyp3a family or by carbonyl reductases to doxorubicinol and is
further metabolized by Cyp3a enzymes to inactive aglycone
metabolites66. Additionally, transcriptional activation of PXR by
either overexpressing a constitutively active PXR protein or
binding of rifampicin to the wild-type hPXR results in decreased
sensitivity to doxorubicin39,67. Vinblastine is metabolized by
CYP3A4 and CYP3A5 to inactive metabolites68. Pretreatment
with a PXR agonist decreases the sensitivity of cancer cells to
vinblastine treatment, whereas siRNA knockdown of PXR
increases their sensitivity to vinblastine51,56. Together, these
results clearly demonstrate the roles of PXR in regulating the
efﬁcacy of chemotherapeutic agents.3. Structural, functional, and expression characteristics of
PXR transcript variants
The PXR gene located on chromosome 3 encodes multiple
transcript variants, resulting in structurally and functionally
Table 1 Examples of hPXR agonists.
Compound Description (indication, drug class, etc.) Reference
12-Ketolithocholic acid Bile salt found in humans Krasowski et al. (2005)24
3-Keto-7α,12α-dihydroxy-5α-cholanic acid Bile salt found in sea lamprey Krasowski et al. (2005)24
5α-Cyprinol 27-sulfate Bile salt found in zebraﬁsh Krasowski et al. (2005)24
5β-Pregnane-3,20-dione Steroid hormone Jones et al. (2000)25
5β-Scymnol 27-sulfate Bile salt found in cartilaginous ﬁsh Krasowski et al. (2005)24
7,12-Diketolithocholic acid Bile salt found in humans Krasowski et al. (2005)24
7-Ketodeoxycholic acid Bile salt found in humans Krasowski et al. (2005)24
7-Ketolithocholic acid Bile salt found in humans Krasowski et al. (2005)24
Carbemazepine Epilepsy Luo et al. (2002)26
Cholic acid Bile salt found in humans Krasowski et al. (2005)24
Clotrimazole Anti-fungal Xie et al. (2000)27; Luo et al. (2002)26; Xie et al.
(2003)28; Jones et al. (2000)25
Corticosterone Glucocorticoid Jones et al. (2000)25
Cyproterone acetate Antineoplastic (prostate); androgen
disorders, steroidal anti-androgen
Jones et al. (2000)25
Deoxycholic acid Bile salt found in rabbit Krasowski et al. (2005)24
Dexamethasone Glucocorticoid Xie et al. (2000)27; Luo et al. (2002)26
Dexamethasone-t-butyl acetate Glucocorticoid Synold et al. (2001)29; Luo et al. (2002)26
Estradiol Steroid hormone Luo et al. (2002)26
Glycolithocholic acid Bile salt found in humans Krasowski et al. (2005)24
Glycolithocholic acid 3-sulfate Bile salt found in humans Krasowski et al. (2005)24
Hyodeoxycholic acid Bile salt found in many mammals Krasowski et al. (2005)24
Hyperforin St. John's Wort; herbal supplement
commonly used for depression
Luo et al. (2002)26
Lithocholic acid Bile salt found in humans Krasowski et al. (2005)24
Lithocholic acid 3-sulfate Bile salt found in humans Krasowski et al. (2005)24
Lithocholic acid acetate Bile salt found in humans Krasowski et al. (2005)24
Lithocholic acid acetate methyl ester Bile salt found in humans Krasowski et al. (2005)24
Mifepristone (RU486) Pregnancy termination, steroidal
antiprogesterone
Xie et al. (2000)27; Jones et al. (2000)25
Nonylphenol Anthropogenic environmental estrogen Mota et al. (2011)30
Paclitaxel (Taxol) Anti-neoplastic Synold et al. (2001)29; Luo et al. (2002)26
Petromyzonol 24-sulfate Bile salt found in sea lamprey Krasowski et al. (2005)24
Phenobarbital Epilepsy Jones et al. (2000)25; Luo et al., (2002)26
Pheytoin Seizure disorders Luo et al. (2002)26
Piperine Component of the spice, black pepper Wang et al. (2013)31
Pregnenolone Steroid hormone Jones et al. (2000)25
Progesterone Steroid hormone Jones et al. (2000)25
Rifampicin A component of the ﬁrst line anti-
tuberculosis therapy
Jones et al. (2000)25; Synold et al. (2001)29; Xie et al.
(2000)27; Xie et al. (2003)28; Luo et al. (2002)26
Ritonavir HIV, protease inhibitor Luo et al. (2002)26
Spironolactone Diuretic, steroidal anti-mineralocorticoid Jones et al. (2000)25
SR12813 Dyslipidemia, HMG-CoA inhibitor Jones et al. (2000)25; Synold et al. (2001)29
Sulfadimidine Antibiotic, sulfonamide Luo et al. (2002)26
Sulﬁnpyrazone Gout Luo et al. (2002)26
Taurochenodeoxycholic acid Bile salt found in humans Krasowski et al. (2005)24
Taurohyodeoxycholic acid Bile salt found in many mammals Krasowski et al. (2005)24
Taurolithocholic acid Bile salt found in humans Krasowski et al. (2005)24
Trans-nonachlor (Chlordane) Pesticide Jones et al. (2000)25
Troglitazone Diabetes (withdrawn), thiazolidinedione Jones et al. (2000)25
Troleandomycin Antibiotic, macrolide Luo et al. (2002)26
α-Muricholic acid Bile salt found in rat Krasowski et al. (2005)24
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transcript variants of PXR in human livers has led to the
postulation that these variants, which may have different transac-
tivation activity, contribute to interindividual variability in the
expression of drug-metabolizing enzymes and efﬂux transporters,
such as CYP3A4 and P-gp69. Recent work has focused on four of
these mRNA transcript variants. The hPXR gene (NC_000003.12,Fig. 1) is located on chromosome 3q12-q13.3 and consists of
approximately 38,000 base pairs69. PXR1 mRNA possesses the
noncoding exon 1a of the hPXR gene and is transcribed into an
mRNA of approximately 4400 nucleotides (NM_003889), which
is then translated into a protein of 434 amino acids using a CTG
start codon in exon 2 (NP_003880). PXR3 mRNA, a splicing
variant of PXR1, originates from exon 1a of the hPXR gene, which
Figure 1 The human PXR gene locus and mRNA transcripts 1–4. Exons are represented as rectangles; the region of exon 5 that is not expressed
in variant 3 is shown in purple, and the alternative positions of exon 1 are shown in red and green.
C. Trent Brewer, Taosheng Chen444contains a 111-base pair (bp) deletion at the 50 end of exon 5, due
to preferential usage of a cryptic splice acceptor site within exon 5,
and is transcribed into an mRNA of approximately 4300 nucleo-
tides (NM_033013), which is translated into a protein of 397
amino acids (NP_148934) with a deletion of 37 amino acids in the
LBD of variant 137,69. The 37-amino acid deletion in human PXR3
corresponds to a 41-amino acid deletion in the LBD of the
corresponding mouse PXR variant3. PXR2 mRNA originates from
the exon 1b of the hPXR gene and is transcribed into an mRNA of
2800 nucleotides (NM_022002), which is translated into a protein
of 473 amino acids using a ATG start codon in exon 1b
(NP_071285) that contains an additional 39 amino acids at the
N-terminus, as compared to PXR169,71,72. PXR1 and PXR2
variants share exon 2 through exon 9 therefore they have identical
LBD and DNA-binding domain. Many other PXR variants have
been described, including PXR4, also known as short PXR
(sPXR), a newly identiﬁed 37-kDa short PXR protein containing
322 amino acids that is translated from exon 4 to exon 9 (cDNA
AK122990)72. The naming of different PXR transcript variants and
their corresponding abbreviations, though mostly consistent, varies
between authors; please refer to the “Abbreviations” section for
the naming scheme used throughout this article.
PXR splice and transcript variants differ in their effects on target
gene transcription7,38,39,70. PXR3 lacks the activity of PXR1 in
terms of both gene transactivation activity and protein–protein
interactions7,38,39,70,73, whereas the protein encoded by the PXR2
mRNA has comparable activity to the main protein, PXR17,38,70.
Similarly to PXR3, PXR4 has been shown to lack gene transacti-
vational activity, but, in contrast to PXR3, it has an intact LBD72.
These observations and the lack of exhaustive study into the
functions of PXR transcript variants highlight the necessity of
investigating the functions of these variant proteins and transcripts
and their effects on drug metabolism.
The PXR transcript variants possess distinct and overlapping
functionality. PXR2 was as effective as PXR1 in mediating
transcription of CYP3A77. Transcription of the UGT1A family
increased in cells transfected with PXR1 and PXR2, but this was
not consistent between UGT1A family members: Whereas
UGT1A1, UGT1A3, UGT1A4, and UGT1A6 mRNA were induced
to various extents by PXR1 and PXR2 in response to rifampicin
treatments, UGT1A9 mRNA was not induced by rifampicin7.
PXR3 did not activate CYP3A7 or UGT1A mRNA expression7, but
when PXR3 was cotransfected with PXR1, it displayed a dominantnegative effect on PXR1 activation of CYP3A4 induced by
rifampicin39. Although PXR3 binds to PXR response element, it
does not activate the expression of a luciferase reporter construct
under the control of the CYP3A4 promoter (CYP-Luc)39. In
addition, it binds to corepressors but not coactivators39. One
study69 found 9 variants of PXR1, 7 of which had deletions in
exon 5. PXR3 results from splicing of PXR1, whereas PXR2 is
generated by an alternate transcription start site and has a ﬁrst exon
distinct from that of PXR1. No publications exist that further
investigate the PXR variants 5–9. Stable transfection of HepG2
and LS180 cells with PXR1, but not with PXR3, resulted in an
increase in CYP3A4, MDR1, CYP2B6, and UGT1A1 mRNA in
both the absence and presence of the PXR agonist rifampicin38,39.
The expression proﬁles of the main PXR transcript variants have
not been fully elucidated, nor have the implications of the 50
diversity among the transcripts been fully investigated. There are
data available on the organism-wide expression proﬁle for variants
1 and 3, but the expression of other variants has been quantiﬁed
only in the liver9,38,40,72. Quantiﬁcation of PXR2 mRNA in a
larger sample (n ¼ 56) found that PXR2 represented, on average,
approximately 15% of the total PXR transcripts in the liver,
although this proportion was as high as 60% in some cases38.
The average mRNA level of PXR3, which lacks the transactivation
activity of PXR1 on inducing CYP3A470 accounts for 7% of the
total PXR transcripts in the liver9. As PXR transcript variants 1 to
4 have identical 30 regions, it would be predicted that similar
regulatory mechanisms act on this region in all variants. However,
the 50 region of the PXR transcripts differs between PXR1 and
PXR240,71,74, and this 50 diversity may contribute to differential
regulation by transregulatory factors at both the genomic (i.e.,
gene) and post-transcriptional (i.e., mRNA) levels74. When 50
rapid ampliﬁcation of cDNA ends (RACE) sequencing was
performed to map the 50 untranslated region (UTR) of PXR
transcripts, putative transcription factor binding sites were found
upstream of the PXR2 ﬁrst exon that were distinct from those in
the upstream region of the PXR1 ﬁrst exon74. As mentioned
previously, PXR1 contains a noncoding exon 1a and uses a CTG
start codon located in exon 274. However, PXR2 contains exon 1b
and an ATG start site that results in a protein with an N-terminal
addition of 39 amino acids (as compared to variant 1)74. The
alternating use of exons 1a and 1b results in distinct 50 regions in
PXR1 and PXR274. The characterization of the upstream region of
PXR2 revealed a promoter region 1.5 kb upstream of the major
PXR variants: the impact on drug metabolism and therapeutic responses 445PXR2 transcript transcription start site that displayed gene trans-
activation activity when placed upstream from a luciferase gene in
a reporter construct75. A search of the TRANSFAC transcription
factor database (http://www.gene-regulation.com/pub/databases.
html) also revealed consensus binding sites for hepatocyte nuclear
factor 1 (HNF1), HNF3β, and HNF4 in this 1.5-kb region that is
required for activating luciferase expression75. Further character-
ization of this promoter region by sequential deletion revealed that
a putative HNF1 response element was required for luciferase
expression75. Additionally, putative TATA boxes and consensus
sites for HNF-3β, octamer factor 1 (Oct-1), CCAAT/enhancer
binding protein β (C/EBPβ), and glucocorticoid receptor (GR),
were found upstream of the major transcription start site identiﬁed
for PXR174. In another study, the region upstream of the
transcription start site of PXR1 containing putative transcription
factor binding sites displayed promoter activity when placed
upstream of a luciferase gene and transfected into HepG2 cells71.
The authors also mapped the minimal essential region for promoter
activity to a 160-bp region upstream of the transcription initiation
site, showing that this region also binds to nuclear proteins and
that mutations of this region disrupt protein binding and reduce
promoter activity. Alternative promoter use would account for the
multiple 50 ends of the transcripts for PXR1 and PXR274. The 50
regions for PXR1 and PXR2 were later extended, and new
proximal promoters were identiﬁed40. Additionally, the exon
3 region with the CpG island also displays promoter activity by
luciferase reporter assay76, suggesting that transcription factors
may be able to regulate PXR4 differently from the other variants,
as PXR4 lacks exon 3.
Interestingly, a 6-bp deletion (133GAGAAG128) spanning
the putative HNF1 binding sequence upstream of the PXR2
transcription start site74 was reported in a Japanese population75.
This deletion was associated with a complete loss of promoter
activity when conjugated to a luciferase gene and transfected into
HepG2 cells. The allele frequency of the deletion variant was 28%
in both healthy control subjects and patients with aspirin-induced
asthma (AIA), and almost half of the population sampled had this
6-bp deletion, either heterozygously or homozygously. The same
6-bp deletion was further investigated in a Chinese population in
healthy controls and in patients with hepatic carcinoma38. In this
study, the allelic frequency, as determined by analyzing blood
samples (n ¼ 177), in healthy controls (22%) was signiﬁcantly
different from that in patients with hepatic carcinoma (38%). This
research group also reported that PXR2 mRNA represented an
average of 15% of the total PXR mRNA expression, with a range
from 1% to 60%. The 6-bp deletion reduces the levels of PXR2
and, thus, of total PXR and of MDR1 and CYP3A4 mRNA
expression38. The signiﬁcantly higher allelic frequency of the 6-
bp deletion in patients with hepatic carcinoma might also suggest
its correlation with carcinoma formation, possibly as a result of the
reduced capacity for detoxiﬁcation.4. Relation of PXR variant expression and activity in the
context of chemotherapeutic response and carcinogenesis
Organism-wide expression proﬁling studies have revealed an
incomplete correlation between the expression of PXR target
genes and that of the major transcript variant, PXR1 (434
residues). PXR2 (473 residues), which regulates similar target
genes to PXR1, may contribute to this incomplete correlation;
however, an organism-wide expression proﬁle for PXR2 has notbeen attempted9. It is possible that the interindividual and tissue
variation in target gene expression may be related to the tissue-
speciﬁc expression of speciﬁc PXR transcript variants. For
example, PXR1 and PXR3 are, in some instances, not expressed
in tissues that express CYP3A4, whereas PXR2 may be expressed
in those tissues. Similarly, Caco-2 cells only express PXR1
mRNA, whereas HepG2 cells, human jejunum, and human
hepatocytes express PXR1, PXR2, and PXR3 mRNA7. In addition
to tissue-speciﬁc expression, the PXR transcript variants also
display divergent effects on target gene transcription. PXR3 binds
to the PXR response element but fails to activate the expression of
PXR target genes in response to PXR ligands39. Instead, it
functions as a dominant negative interfering with PXR139. PXR1
and PXR2, but not PXR3, induce CYP3A7, UGT1A1, UGT1A3,
and UGT1A4 mRNA in HepG2 and Caco-2 cells in response to
rifampicin7. These data suggested that both PXR1 and PXR2,
although they may be differentially expressed, contribute to the
overall PXR activity7. Conversely, PXR3 and PXR4 lack tran-
scriptional activity in inducing target gene expression39,72. Thus,
the relative expression levels of the PXR transcript variants may
directly affect chemotherapeutic metabolism.
A recent report describes the inverse correlation between the
expression level of PXR4 and the methylation status of a CpG
island upstream of exon 3, as well as the effect of overexpressed
PXR4 protein in reducing cell proliferation markers72. The CpG
island was reported to be methylated in various cell lines and
normal colon tissue, and the methylation status of this region did
not affect PXR1 mRNA expression77. PXR4 contains 322 amino
acids, is homologous to the LBD of PXR1 and PXR2, retains
ligand and coregulator binding capacity, and is detectable in the
nucleus, but it lacks target gene transactivation activity72. These
investigators also found PXR4 to represent approximately 10% of
the total PXR mRNA expressed in human livers. Overexpression
of PXR4 in HepG2 cells decreased cellular proliferation and
rifampicin-induced expression of CYP3A4 and FGF1972. The
authors postulated that PXR4 was a tumor suppressor functioning
as a dominant negative against PXR1. Although no signiﬁcant
difference in expression of PXR4 mRNA was observed in normal
tissue and hepatocellular carcinoma or adenoma, the authors did
observe differences in expression of PXR4 mRNA among certain
tumor subtypes. For example, PXR4 mRNA was decreased in
inﬂammatory hepatocellular adenomas compared to normal livers
or noninﬂammatory subtypes. Interestingly, higher levels of PXR4
mRNA expression were associated with favorable prognostic
indicators and greater disease-free survival, whereas lower levels
of expression in subtypes of hepatocellular carcinoma were
associated with poor prognoses. The authors also observed
decreased expression of PXR4 in the inﬂammatory subtype of
hepatocellular adenoma that is believed to progress to hepatocel-
lular carcinoma as a result of inﬂammatory activation via the JAK/
STAT pathway. These observations suggest that the suppressive
effect of PXR4 on PXR target genes may also extend to
interactions with the NF-κB pathway, a pathway known to interact
with PXR14,72,78,79. PXR4 may thus serve as a prognostic marker
in hepatic carcinoma, as well as playing a role in the malignant
transformation of hepatic carcinomas.
The PXR variants may also display differential behavior in protein–
protein interactions. It has been reported that p53 interacts with PXR1
and represses PXR-mediated transactivation of the CYP3A4 promoter.
However, PXR3 does not interact with p5373. The p53 protein,
mutated in many cancers, is a tumor suppressor that leads to cell cycle
arrest, DNA repair, and apoptosis when activated by a wide array of
C. Trent Brewer, Taosheng Chen446genotoxic stresses80,81. Interestingly, while both the wild-type and
mutated forms of p53 interact with PXR, only the wild-type form
inhibits PXR activity73. Therefore, cell populations with a mutant p53
protein will have higher levels of PXR transcriptional activity and
drug-metabolizing enzymes, such as CYP3A4, possibly rendering
these populations less responsive to chemotherapeutic agents that are
metabolized by CYP3A4. Whether other PXR protein variants interact
with p53 has not been investigated.
As discussed earlier, the differential regulation of PXR1 and
PXR2 resulting from their different 50 UTRs may contribute to the
differential expression of the variants and the levels of total PXR
and its target genes, which might be associated with differential
risk of carcinoma formation and the response of cancer to
chemotherapeutic agents.
Methylation of the PXR promoter was ﬁrst reported in detail in
neuroblastoma76. Neuroblastoma is the most common solid tumor
in children, with advanced stages having an incidence of mortality
greater than 60%82,83. Normal adrenal tissue, the tissue of origin of
neuroblastoma, expresses PXR1 mRNA exclusively76. Hyper-
methylation in CpG-rich exons and promoter regions has been
observed in many cancers and can lead to the transcriptional
inactivation of tumor suppressors84. PXR mRNA expression was
analyzed across a panel of 19 neuroblastoma cell lines, and no
PXR was detected in 14 of the cell lines76. By using bacterial
artiﬁcial chromosome array-based methylated CpG island ampli-
ﬁcation (BAMCA), the promoter of PXR was found to be
methylated in several neuroblastoma cell lines and primary
tumors76. Speciﬁcally, PXR mRNA was expressed in the low-
grade tumors but not in the advanced neuroblastoma cell lines
analyzed. However, PXR mRNA expression increased in the
advanced neuroblastoma cell lines after they were treated with
5-aza-Cyd, an inhibitor of DNA methyltransferase76. The authors
performed bisulﬁte sequencing in the exon 1a region and in a
region of exon 3. Methylation of the exon 3 region was more
frequently detected in advanced tumors, tumors from patients with
a poor prognosis, and tumors from patients who were more than
1 year of age. The methylation status of exon 1a did not correlate
with PXR mRNA expression. However, hypermethylation of the
exon 3 region was detected in cell lines lacking PXR mRNA
expression (IMR32 and SH-SY5Y), whereas hypomethylation, as
well as PXR mRNA expression, was detected in a normal
lymphoblast cell line and two neuroblastoma cell lines (SK-N-
AS and SK-N-KP). The exon 3 region with the CpG island
exhibited promoter activity. Additionally, there was no detectable
difference in the methylation status of the exon 1a region among
these cell lines. PXR1 and PXR2 mRNA were expressed in cell
lines in which the PXR promoter is unmethylated, but not in cell
lines with methylated PXR promoters. In cell lines with methylated
PXR promoter, the expression of PXR1 mRNA, but not of PXR2
mRNA, was restored by the treatment with 5-aza-Cyd. PXR2 was
detected in the hypomethylated (SJ-N-KP and SK-N-AS) cell lines
and not in the hypermethylated ones (SJ-N-GC and SMS-KAN),
whereas PXR3 mRNA was not expressed in any of the cell lines,
regardless of their methylation status or whether they were treated
with 5-aza-Cyd. Consequently, the methylation status of separate
regions of the PXR gene differentially regulates the expression of
speciﬁc PXR variants. In this study, the ectopic overexpression of
PXR decreased cell proliferation, suggesting that PXR functions as
a tumor suppressor76. However, whether this ﬁnding is speciﬁc to
neuroblastoma cell lines is unclear.
In colon cancer cell lines, PXR promoter methylation was
associated with PXR mRNA and CYP3A4 mRNA expressionlevels77. Moreover, the PXR promoter was less methylated and
PXR and CYP3A4 mRNA expression levels were correspondingly
higher in cancerous colon tissues than in adjacent normal tissues.
In a xenograft model of colon cancer, PXR activation correlates
with the growth of both human colon tumor cell lines and primary
human colon cancer tissue. PXR potentially functions as an
oncogene85. In colon cancer cell lines (LS180, LoVo, Caco-2,
HCT116, HT29, and SW48), PXR and CYP3A4 mRNA levels
were associated with hypermethylation of a CpG-rich sequence in
the promoter of PXR and were increased after treatment with
5-aza-dC77. The cell lines that express high levels of PXR1 and
low levels of PXR2 and PXR3 have mostly methylated CpG-rich
sequences in exon 1b and in the intron of the 30 end of exon 1b.
However, a mostly unmethylated CpG-rich sequence exists in
exon 1a and in the intron of the immediate 30 end of exon 1a in the
cell lines with higher expression of PXR (LS180 and LoVo)77.
Thus, it would seem that the mRNA expression of different PXR
variants could be differentially regulated by methylation. It would
be expected that methylation of the CpG-rich sequences in and
around exon 1a might speciﬁcally affect the expression of PXR1
mRNA and PXR3 mRNA, whereas the methylation status of and
near exon 1b would affect the expression patterns of PXR2
mRNA. In colon cancer cells excised from colonic tissue samples,
the CpG island within the exon 3 region is the most methylated
region of the PXR gene, whereas the CpG-rich sequence around
exon 1a is the most unmethylated region77. The CpG-rich
sequence around exon 1b is methylated in these colon cancer
cells, and this may correlate with low PXR2 mRNA expression.
Additionally, the methylation of the CpG island within exon
3 seen in cell lines77 may be associated with low expression of
PXR4 and, subsequently, with higher expression observed after
treatment with a demethylating agent72. Therefore, determination
of the protumor effect of PXR in colon cancer may involve a
complex series of events that requires a speciﬁc relative expression
pattern of multiple transcript variants. Additional analysis of the
methylation of PXR variants in different tumor types is warranted
to further establish the correlation between methylation and
expression of PXR and tumor development, as well as tumor
response to chemotherapeutic agents.5. Conclusions
It is clinically and scientiﬁcally important to elucidate the
functions of the PXR variants in order to predict the outcome of
ligand activation of PXR and the role of PXR in various model
systems. PXR is activated by structurally and functionally diverse
ligands that are associated with and prescribed in a multitude of
disease states. A greater understanding of the roles of the hPXR
transcript variants would greatly contribute to predicting therapeu-
tic failure of cotherapies arising from xenosensor-mediated
decreases in drug bioavailability or increases in toxicity. For
example, high overall PXR expression and low PXR3 (which
functions in a dominant negative manner) expression may result in
decreased drug bioavailability whereas high overall PXR expres-
sion and high PXR3 expression (compared to transcriptionally
active variants) would be expected to result in increased drug
bioavailability. PXR1 plays a well-described role in the detoxify-
ing drug metabolism pathways of cancer therapeutics and can
cause treatment failure at high levels of expression. PXR2 has
similar effect on target gene transactivation but has not been fully
characterized in terms of coregulator recruitment, ligand response,
PXR variants: the impact on drug metabolism and therapeutic responses 447protein–protein interactions, or organism-wide tissue expression.
PXR3 has been reported to recruit corepressors but does not
similarly participate in the protein–protein interactions associated
with PXR1 or transactivate PXR target genes. However, it is
unknown whether the dominant negative effect of PXR3 plays a
signiﬁcant pathophysiologic or physiologic role. PXR4 has been
reported to compete with PXR1 in binding to ligand and
coactivators to exert a dominant negative effect, as has PXR3
with respect to PXR1 transactivational activity. Several of these
transcripts have been implicated in cancer pathogenesis, with
PXR1 expression being a negative prognostic factor in some but
not all cancers because of its role in drug metabolism and
transport. There have been many contradictory reports concerning
the effects of PXR1 on cellular proliferation and apoptosis; these
effects may be more clearly deﬁned by investigating the roles of
the variants in these various model systems. PXR polymorphisms,
the use of alternate promoters, and splicing variations have not
been fully elucidated in terms of expression across disease states
and transactivation proﬁles of target genes. Future studies inves-
tigating the role of PXR on drug metabolism would be remiss not
to evaluate multiple transcript variants and the resultant proteins.
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